AzTrials
AzTrials

Cervical CancerHPINCT00937547

Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela

An observational study of Cervical Cancer, run by Instituto Oncologico Luis Razetti at 2 sites in Venezuela.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. Hypothesis: If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries. 2. Read more about this study

Who is it for?
Any age, women only
Conditions the study is for
Cervical Cancer
How many people
329 participants
Where
2 sitesVenezuela
Study dates
Nov 2009to Jul 2011
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: cervical samples

Who may be able to join

  • paraffin blocks of 329 patients with histologic diagnosis of CIN 2, CIN 3 or Stage I cervical cancer. -

Who cannot join

  • -

Trial locations and contacts

2 sites in 1 country.

Venezuela2 sites
  • Instituto Oncologico Luis razetti

    Caracas, DF

  • Jorge Sanchez Lander

    Caracas, Miranda, 1060

Other trials in Venezuela

About this study

Official title: Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.

  1. Hypothesis: If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer worldwide, the genotypes associated with cervical cancer in Venezuela would be the same types found in other countries.
  2. Objectives:

Primary objective:

The objective of this investigation is to determine the presence and genotypes of HVP infection in cervical intraepithelial neoplasia grade 2/3 (CIN 2/3), and Stage I cervical epidermoid carcinoma and cervical adenocarcinoma.

Specific objectives:

To establish the presence of HPV in cervical cancer patients in Venezuela by geographic distribution.

To establish which HPV types are linked with cervical cancer in Venezuela by geographic distribution.

Read the detailed description

In Venezuela, cervical cancer is the second leading cause of cancer mortality in women. In developed countries, although it is not the first cause of cancer mortality, occupies a remarkable place in the neoplastic pathology (Cannistra, 1996; Dey, 1998).

Human Papilloma Virus (HPV) is involved in the development of cervical cancer, specially oncogenic types 16 and 18 (Koskela, 2000; Markowska, 1999).

To date, it is still unknown which HPV types are more frequent in Venezuela. Several studies made in this country concluded that HPV 16 is the predominant type in cervical pathology (Graterol 2006, Correnti 1997, Muñoz 2003), but there has not been performed a HVP genotyping to detect all the types involved in patients with cervical cancer. Neither has been establish which HPV types are more frequently involved in genital warts in Venezuela.

The goal of this investigation is perform a genotypification of HPV in cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela to determine which types are more frequently related to this disease in our country.

  1. STUDY DESIGN:

4.1. Collection of cervical samples:

  1. Previous ethics committee approval (Instituto Venezolano de Investigaciones Cientificas and Instituto de Oncología Luis Razetti), we are going to collect paraffin blocks of 300 patients with histological diagnosis of CIN 2-3 or Stage I cervical cancer.

The samples will be obtained from archives of the Pathology Units of the following medical centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad Central de Venezuela(Caracas), Hospital Oncológico Pérez Carreño (Valencia), Maracaibo, Barquisimeto, Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.

Inclusion criteria:

  1. Paraffin blocks with CIN 2/3, and Stage I cervical cancer biopsies obtained between 2001 and 2011.
  2. Properly blocks identification in order to obtain personal and clinical patient information.

4.2. Molecular biology procedures:

  1. Histologically handling of tissue: previous identification of pathologic lesions as described in inclusion criteria by an expert pathologist (sample with lesion but without necrosis), the paraffin block will be cut into 5 to 7 µm slides with new blades and gloves for each cut. It will be obtain 1 slides that will be distributed as follows: one sample will be send to Laboratorio de Virología Molecular del Instituto Venezolano de Investigaciones Científicas; the remained sample will be kept for further evaluation if is necessary. Each slide will be placed in a proper container and will be identified by a serial number in order to preserve patient intimacy and avoid biased results.
  2. Deparaffinisation as described in Coombs 1999.
  3. Tissue digestion, DNA extraction and precipitation as described in Gravitt 2000.
  4. HPV genotyping will be detected by INNOLiPA system. The results will be correlated with clinical information.
Conditions
Cervical Cancer
Keywords
cervical cancer, Human Papillomavirus Infection
Medical subject headings
Uterine Cervical Neoplasms, Papillomavirus Infections

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HPV Identification

    HPV distribution was identified in CIN2, CIN3 and invasive cervical cancer

    Measured: 6 months

  2. HPV Type 16

    Number of biopsies positive to HPV 16.

    Measured: 6 months

  3. HPV Type 18

    Number of biopsies positive to HPV 18.

    Measured: 6 months

  4. HPV Type 31

    Number of biopsies positive to HPV 31.

    Measured: 6 months

  5. HPV Type 33

    Number of biopsies positive to HPV 33.

    Measured: 6 months

  6. HPV Type 45

    Number of biopsies positive to HPV 45.

    Measured: 6 months

  7. HPV Type 58

    Number of biopsies positive to HPV 58.

    Measured: 6 months

  8. HPV Type 51

    Number of biopsies positive to HPV 51.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jul 2009 (estimated)
  2. Study startNov 2009
  3. Primary completionJul 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
329 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00937547
Sponsor's protocol ID
CERVICAL CANCER AND HPV
Acronym
HPI
Status last verified
Nov 2012
First submitted
10 Jul 2009
Last updated
4 Dec 2012
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cervical Cancer, run by Instituto Oncologico Luis Razetti at 2 sites in Venezuela.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Venezuela. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Nov 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HPV Identification (time frame: 6 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in